Academic literature on the topic 'Adjuvant hormone therapy'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Adjuvant hormone therapy.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Adjuvant hormone therapy"
Boyages, John, and Ken W. Tiver. "ADJUVANT SYSTEMIC THERAPY IN BREAST CANCER PART 1: ADJUVANT HORMONE THERAPY." ANZ Journal of Surgery 62, no. 5 (May 1992): 354–63. http://dx.doi.org/10.1111/j.1445-2197.1992.tb07203.x.
Full textGupta, S., M. Singh, Amish Vora, G. Babu, M. Walia, V. Nautial, R. Saha, et al. "Practical consensus recommendations on duration of adjuvant hormonal therapy in breast cancer." South Asian Journal of Cancer 07, no. 02 (April 2018): 142–45. http://dx.doi.org/10.4103/sajc.sajc_122_18.
Full textLatif, Asma, Alexander C. Small, Erin L. Moshier, Kerin B. Adelson, George Raptis, James H. Godbold, William K. Oh, and Matt D. Galsky. "Practice patterns in the use of adjuvant therapy for post-menopausal early-stage breast cancer in the pre- and post-Oncotype DX era." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): e21032-e21032. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e21032.
Full textZeng, Erwei, Wei He, Jenny Bergqvist, and Kamila Czence. "Abstract P3-12-04: Extending therapy after 5-year adjuvant hormone therapy in breast cancer patients: A population-based study." Cancer Research 82, no. 4_Supplement (February 15, 2022): P3–12–04—P3–12–04. http://dx.doi.org/10.1158/1538-7445.sabcs21-p3-12-04.
Full textWiltshaw, E. "Adjuvant hormone therapy in ovarian cancer." Biomedicine & Pharmacotherapy 46, no. 4 (January 1992): 176. http://dx.doi.org/10.1016/0753-3322(92)90032-3.
Full textBlomqvist, Carl P., Inkeri Elomaa, and Pentti Rissanen. "Adjuvant Hormone Therapy in Breast Cancer." Annals of Medicine 24, no. 2 (January 1992): 91–96. http://dx.doi.org/10.3109/07853899209148333.
Full textKovalenko, E. I., I. B. Kononenko, A. V. Snegovoi, O. P. Grebennikova, and L. V. Manzyuk. "Adverse effects of adjuvant endocrine therapy." Medical Council, no. 10 (July 19, 2018): 64–69. http://dx.doi.org/10.21518/2079-701x-2018-10-64-69.
Full textLoibl, S., G. von Minckwitz, and M. Kaufmann. "Adjuvant hormone therapy following primary therapy for endometrial cancer." European Journal of Cancer 38 (September 2002): 41–43. http://dx.doi.org/10.1016/s0959-8049(02)00281-2.
Full textSlonimskaya, E. M., A. V. Doroshenko, P. V. Kazantseva, N. A. Tarabanovskaya, and R. Yu Vernadsky. "Individual approach to choosing an appropriate regimen of adjuvant hormone therapy in patients with early-stage breast cancer." Tumors of female reproductive system 14, no. 3 (October 16, 2018): 48–54. http://dx.doi.org/10.17650/1994-4098-2018-14-3-48-54.
Full textCutolo, Maurizio. "SEX HORMONE ADJUVANT THERAPY IN RHEUMATOID ARTHRITIS." Rheumatic Disease Clinics of North America 26, no. 4 (November 2000): 881–95. http://dx.doi.org/10.1016/s0889-857x(05)70174-5.
Full textDissertations / Theses on the topic "Adjuvant hormone therapy"
He, Ru, and 何茹. "Effectiveness and toxicity of aromatase inhabitors [i.e. inhibitors] in adjuvant therapy for hormone receptor positive postmenopausalbreast cancer: a meta-analysis." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2011. http://hub.hku.hk/bib/B46936026.
Full textWirth, Manfred, and Michael Fröhner. "A Review of Studies of Hormonal Adjuvant Therapy in Prostate Cancer." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-134738.
Full textDieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich
Wirth, Manfred, and Michael Fröhner. "A Review of Studies of Hormonal Adjuvant Therapy in Prostate Cancer." Karger, 1999. https://tud.qucosa.de/id/qucosa%3A27593.
Full textDieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
Chari, Venkatesh Vasu. "Drug Targets to Improve the Outcome of Hormonal Adjuvant Therapy in Breast and Prostate Cancers." University of Toledo Health Science Campus / OhioLINK, 2013. http://rave.ohiolink.edu/etdc/view?acc_num=mco1384738922.
Full textSalazar, Marcela d'Alincourt. "Genomic Effects of Hormonal Adjuvant Therapies that Could Support the Emergence of Drug Resistance in Breast Cancer." University of Toledo Health Science Campus / OhioLINK, 2010. http://rave.ohiolink.edu/etdc/view?acc_num=mco1280929084.
Full textBhosle, Monali Jaysing. "Outcomes associated with adjuvant hormonal therapy: are they any differences between black and white women with primary breast cancer?" The Ohio State University, 2007. http://rave.ohiolink.edu/etdc/view?acc_num=osu1189093998.
Full textBhosle, Monali Jaysing. "Outcomes associated with adjuvant hormonal therapy are there any differences between black and white women with primary breast cancer? /." Columbus, Ohio : Ohio State University, 2007. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1189093998.
Full textCHENG, WEN-HSUEN, and 鄭文雪. "The Experience of Adjuvant Hormonal Therapy in Women with Breast Cancer." Thesis, 2009. http://ndltd.ncl.edu.tw/handle/49832653497228692742.
Full text國立台北護理學院
護理研究所
98
This study was conducted by the method of qualitative analysis of the data collected by in-depth interviews of the women with breast cancer who were taking adjuvant hormonal therapy. The qualitative analysis used constant comparative method for data collection and subsequent data analysis. The target population of this study were women with confirmed pathological diagnosis of breast cancer, regardless of whether she had received chemotherapy in the past; who’s currently receiving adjuvant oral hormonal therapy for at least six months, and was willing to share their experience by participating in this study. This study collected data from a total of 11 cases. The researcher was the data collector. The research tools involved the general information of each case and the open-ended interview guide. Participants decided where and when the interview took place. Data was collected by in-depth face to face interview and the content was recorded by a voice recorder. The average time for each interview was about 65 minutes. For insuring the validity of this study, the method developed by Lincoln and Guba (1985) was used to evaluate and confirm the credibility, transferability, dependability, and confirmability of the study. The results of this study covered three aspects of the experience of the breast cancer patients who received adjuvant hormonal therapy, which includes: the experience of coexistence with the medication, life style adjustment after taking the medication, and restructuring for the meaning of life. Hopefully, this study will raise the cognition of the medical staff for the the experience of adjuvant hormonal therapy in women with breast cancer and provide a comprehensive and holistic patient care.
Huang, Chiung-Hsuan, and 黃瓊萱. "The Health Needs among Breast Cancer Women Receiving Adjuvant Hormonal Therapy." Thesis, 2007. http://ndltd.ncl.edu.tw/handle/10191090706627615785.
Full text國立台北護理學院
護理研究所
95
Breast cancer patients undergoing adjuvant hormone therapy is increasing recently. The health needs of these patients have their specific health concerns, such as the management of their menopausal symptoms. However, little studies were conducted in Taiwan. The purposes of this study were to explore the health needs and related factors such as demographic data, health status and menopausal disturbance symptoms among breast cancer patients undergoing adjuvant hormone therapy in Taiwan. Sixty-five women were recruited. The collected data were analyzed through the statistical software, SPSS 14.0. The findings of this study were as follows: 1.The mean age of the women was 48.40. The average time of post-operation was 2.40 years. All women were undergoing the adjuvant hormone therapy. Average duration of using adjuvant hormone therapy was 1.89 years. 75% of the women have received chemotherapy and 47.69% of women have been treated by radiotherapy. 2.The satisfaction level of the holistic health needs was at the level of moderate to good. The order of satisfaction level of the health needs was: psychosocial support needs, information needs and physical needs. The top five issues of un-meted health needs were: “how to prevent from menopausal heart diseases”, “how to manage menopausal symptoms such as bone and joint, mental and vasomotor symptoms” and “How to use complimentary and alterative therapy to prevent from breast cancer recurrence”. Women expressed that they needed the knowledge of prevent from breast cancer recurrence and body discomforts such as insomnia, hot flash and joint pain during receiving hormone therapy. 3.Women reported that their health status were worse than before. Self-perceived health status was at moderate good level. The women perceived occasionally negative feelings. There is little influences on daily activity except the exertion of cleaning, wiping the floor, carrying heavy bag. The women expressed that their menopausal disturbance symptoms were at ‘mild’ disturbcance level. The rank of menopausal disturbances symptoms was: sleep disturbance, difficulty in falling asleep, forgetfulness, insufficient sleep and irregular menses. 4.The satisfactions of the holistic health needs were positively related with the time of using hormone therapy, self-perceived mental health status and menopausal disturbance symptoms and negatively related with menopausal disturbance symptoms. 5.The mental health status, reproductive menopausal symptoms and time of using adjuvant hormone therapy explained 47.5% of the variance of the satisfaction of holistic health needs. This study suggests health providers to provide active support and information to breast cancer women about possible menopausal symptoms and how to prevent from the recurrence of breast cancer including self-examination of recurrence symptoms, complimentary and alterative therapy.
SU, CHIU-PING, and 蘇秋萍. "Relation of cognitive function and functional health status in women receiving adjuvant hormonal therapy." Thesis, 2010. http://ndltd.ncl.edu.tw/handle/72568682976163617258.
Full text國立台北護理學院
護理研究所
98
The adjuvant hormonal therapy is one of common treatments for breast cancer. The women with breast cancer often complained about memory loss and attention deficit after cancer treatment. There is limited information about the cognitive function and its relation with functional health. Thus, the purpose of this study was to describe relation of cognitive function and functional status in women receiving adjuvant hormonal therapy. This was a cross-section, descriptive study. A conveniences sample of 129 women with early-stage breast cancer was recruited in a medical center in Taipei. Cognitive function was measured by Montreal Cognitive Assessment (MoCA) to test the visuospatial, memory, attention, language, abstraction and orientation, and by EORTC-CF for perceived cognitive difficulty.. Functional health was measured by SF-36. All three instruments were in Traditional Chinese and demonstrated Cronbach’s α of 0.70 – 0.82. Data were analyzed by using SPSS 16.0. The women had a mean age of 52.2 and were 2.5 since diagnosis. A majority of them were married, with high-school-or-above education and had stage II breast cancer (56.6%), MRM (53.5%), chemotherapy (74.4%) and Tamoxifen (75.2%). Results showed that the women reported a mild to moderate cognitive difficulty (67.5±21.4); 41.9% of them performed less than 26 on MoCA after adjusted with education; and 24% were compatible with mild cognitive deficit and greater than 1/4 can’t perform visualspatial. After control with chronic illness, the visualspatial, memory, abstraction and EORTC-CF were significantly related to the role limitations due to physical function.
Books on the topic "Adjuvant hormone therapy"
1944-, Miller William R., and Ingle James N. 1944-, eds. Endocrine therapy in breast cancer. New York: Marcel Dekker, 2002.
Find full textCassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, and Gareth Morris-Stiff. Targeted and biological therapies. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0009.
Full text(Editor), W. Jonat, M. Kaufmann (Editor), and K. Munk (Editor), eds. Hormone-Dependent Tumors: Basic Research and Clinical Studies : 9th International Expert Meeting of the Dr. Mildred Scheel Stiftung Fur Krebsforschung, ... 19 (Contributions to Oncology, Vol 50). S. Karger AG (Switzerland), 1995.
Find full textCassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, Gareth Morris-Stiff, and Madhumita Bhattacharyya. Gynaecological cancers. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0020_update_001.
Full textKulkarni, Kunal, James Harrison, Mohamed Baguneid, and Bernard Prendergast, eds. Breast surgery. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198729426.003.0021.
Full textCavalli, Franco, ed. Endocrine Therapy Of Breast Cancer (ENDOCRINE THERAPY OF BREAST CANCER). Springer, 1989.
Find full textFrancesco, Cavalli, ed. Endocrine therapy of breast cancer III. Berlin: Springer-Verlag, 1989.
Find full textMIller/Ingle. Endocrine Therapy in Breast Cancer. Informa Healthcare, 2002.
Find full text(Editor), James N. Ingle, and Mitchell Dowsett (Editor), eds. Endocrine Therapy for Breast Cancer. Informa Healthcare, 2004.
Find full textBook chapters on the topic "Adjuvant hormone therapy"
Pritchard, K. I., J. A. Roy, and C. A. Sawka. "Sex Hormones and Breast Cancer: The Issue of Hormone Replacement." In Adjuvant Therapy of Breast Cancer V, 285–93. Berlin, Heidelberg: Springer Berlin Heidelberg, 1996. http://dx.doi.org/10.1007/978-3-642-79278-6_32.
Full textShimada, Andrea K., João Victor Machado Alessi, Bruna Zucchetti, and Artur Katz. "Adjuvant Hormone Therapy for Breast Cancer." In Breast Diseases, 479–87. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-13636-9_58.
Full textKreuser, E. D., W. D. Hetzel, F. Porzsolt, and R. Hautmann. "Reproductive Toxicity with and Without Administration of Luteinizing-Hormone-Releasing Hormone Agonist During Adjuvant Chemotherapy in Patients with Germ Cell Tumors." In Cancer Therapy, 292–302. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-73721-3_34.
Full textBoccardo, F., A. Rubagotti, D. Amoroso, M. Mesiti, P. Pacini, L. Gallo, P. Sismondi, et al. "Italian Breast Cancer Adjuvant Chemo-hormone Therapy Cooperative Group Trials." In Recent Results in Cancer Research, 453–70. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-45769-2_44.
Full textBolla, M., Th M. de Reijke, A. Zurlo, and L. Collette. "Adjuvant Hormone Therapy in Locally Advanced and Localized Prostate Cancer: Three EORTC Trials." In Controversies in Uro-Oncology, 81–86. Basel: KARGER, 2002. http://dx.doi.org/10.1159/000061332.
Full textAbdi, E. A., H. Jenkins, and C. May. "Relationship of Breast Cancer Hormone Receptors, Menopausal Status, and Adjuvant Therapy to Site(s) of Recurrence and Survival." In Fundamental Problems in Breast Cancer, 177–85. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4613-2049-4_20.
Full textThakar, Alok. "Adjuvant Chemotherapy and Hormonal Therapy." In Juvenile Angiofibroma, 243–50. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-45343-9_19.
Full textGradishar, William J. "Adjuvant Therapy for Breast Cancer: Hormonal Therapy." In Breast Disease, 353–62. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1145-5_24.
Full textZelnak, Amelia B., and Ruth M. O'Regan. "Adjuvant Hormonal Therapy for Early-Stage Breast Cancer." In Cancer Treatment and Research, 63–78. Boston, MA: Springer US, 2008. http://dx.doi.org/10.1007/978-0-387-73161-2_5.
Full textWirth, Manfred P., Oliver W. Hakenberg, and Michael Froehner. "Adjuvant Hormonal Treatment – The Bicalutamide Early Prostate Cancer Program." In Frontiers of Radiation Therapy and Oncology, 39–48. Basel: KARGER, 2008. http://dx.doi.org/10.1159/000139877.
Full textConference papers on the topic "Adjuvant hormone therapy"
Chagpar, AB, JL Lewis, KM McMasters, and MJ Edwards. "Factors influencing the decision to add chemotherapy to adjuvant hormonal therapy in women with hormone receptor-positive breast cancer." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-4105.
Full textFelder, Tisha M., Lincy S. Lal, Dana Stafkey-Mailey, Phoenix Do, Kevin Lu, and Charles L. Bennett. "Abstract A52: Receipt of adjuvant hormonal therapy among Medicaid enrollees diagnosed with hormone-receptor positive breast cancer, 2004-2007." In Abstracts: Fifth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Oct 27–30, 2012; San Diego, CA. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1055-9965.disp12-a52.
Full textLohrisch, C., C. Speers, S. Chia, H. Kennecke, S. Ellard, and S. Tyldesley. "Abstract P1-13-01: Risk of recurrence following 5 years of adjuvant hormone therapy for hormone receptor positive early breast cancer." In Abstracts: Thirty-Sixth Annual CTRC-AACR San Antonio Breast Cancer Symposium - Dec 10-14, 2013; San Antonio, TX. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/0008-5472.sabcs13-p1-13-01.
Full textSuh, Christina H., Sumita Bhatta, Ningqi Hou, Zakiya N. Moton, and Susan Hong. "Abstract A31: Factors associated with compliance to adjuvant hormone therapy for African American and Caucasian women." In Abstracts: Fifth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Oct 27–30, 2012; San Diego, CA. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1055-9965.disp12-a31.
Full textBlok, EJ, A. Charehbili, JR Kroep, CM Seynaeve, CJH van de Velde, and PJK Kuppen. "Abstract P6-01-05: Radiological evaluation of neo-adjuvant endocrine therapy in hormone-receptor positive early breast cancer." In Abstracts: Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.sabcs15-p6-01-05.
Full textKim, Jongjin, Wonshik Han, Hyeong-Gon Moon, Min Kyoon Kim, Eunshin Lee, Tae-Kyung Yoo, Han-Byoel Lee, et al. "Abstract P1-12-13: Factors associated with adherence to adjuvant endocrine therapy in patients with hormone receptor positive breast cancer." In Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.sabcs14-p1-12-13.
Full textMayer, EL, AM DeMichele, H. Guo, KD Miller, HS Rugo, B. Schneider, AG Waks, et al. "Abstract PD5-06: Adjuvant palbociclib plus endocrine therapy for hormone receptor positive/HER2 negative breast cancer: A phase II feasibility study." In Abstracts: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, Texas. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.sabcs17-pd5-06.
Full textHou, Ningqi, Katharine Yao, David J. Winchester, Nora Jaskowiak, David P. Winchester, and Dezheng Huo. "Abstract A62: Secular trends and disparity of adjuvant hormone therapy use for ductal carcinoma in situ: National Cancer Database, 1998–2007." In Abstracts: AACR International Conference on the Science of Cancer Health Disparities‐‐ Sep 18-Sep 21, 2011; Washington, DC. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1055-9965.disp-11-a62.
Full textHe, W., LE Bergman, S. Törnberg, F. Strand, P. Hall, and K. Czene. "Abstract P6-08-20: Non-adherers of mammography screening: Delayed surgery, early discontinuation of adjuvant hormone therapy, and worse breast cancer outcomes." In Abstracts: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, Texas. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.sabcs17-p6-08-20.
Full textTokunaga, E., S. Akiyoshi, C. Koga, Y. Nakamura, K. Taguchi, M. Ishida, and S. Ohno. "Abstract P5-08-47: Clinical outcome of pathological T1N0 breast cancer according to the hormone receptor and HER2 status and adjuvant therapy." In Abstracts: Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.sabcs15-p5-08-47.
Full textReports on the topic "Adjuvant hormone therapy"
Zhang, Meilin, Jian Song, Hongguang Yang, Feng Jin, and Ang Zheng. Adjuvant and neoadjuvant therapy of cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2-negative, early breast cancer: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2022. http://dx.doi.org/10.37766/inplasy2022.11.0008.
Full text